By 2026 , Single Use Bioreactors Market To Grow at a CAGR of 13.5%

Single-use bioreactors available today are robust and offers high performance which is necessary
for the commercial manufacturing of biopharmaceutical products. Improvements in the bioreactor
designs, film technology, sensor systems and stirring mechanisms are resulting in the increasing
adoption of the single-use bioreactors. Manufacturers are also closely working with their customers
to comply with the changing needs such as for next-gen gene and cell therapies, and for continuous
bioprocessing. New generation single-use bioreactors are being designed while keeping in mind the
processes and final drug product perspectives by the end users.
Recent developments in single-use bioreactors by manufacturers are focused on improving mixing,
reducing complexity, and avoid leakage and integrity issues. Improvements in the cell-culture
processes are also leading to the rise in adoption of single-use bioreactors.
Some of the key market players in the report are Sartorius Merck Millipore, Stedim Biotech, GE
Healthcare, Thermo Fisher Scientific, Danaher, Parker Hannifin, Eppendorf, Applikon
Biotechnology, Cesco Bioengineering, Celltainer Biotech, Cellexus, PBS Biotech, Distek, Pierre
Guerin, and Solida Biotech.
Read Report @
Global Single-Use Bioreactors Market to Witness Strong Growth during the Forecast Period
According to the latest report compiled by Transparency Market Research (TMR), the global singleuse bioreactors market is expected to witness robust growth. It is also estimated to increase to
13.5% CAGR throughout the forecast period 2017-2026. The market is also projected to reach US$
1,547.3 million revenue by 2026 end.
The global single-use bioreactors market is segmented on the basis of product type, cells type, end
user and molecule type. Based on the product type, the segmentation consists of media bags, single
use bioreactor systems and filtration assemblies. Among these, single use bioreactor systems are
anticipated to witness significant growth throughout the forecast period. Based on the cells type, the
market is categorized into bacterial cells, mammalian cells, yeast cells, and others. Between 2017
and 2026, mammalian cells are expected to witness the highest growth.
By end user, biopharmaceutical companies are anticipated to emerge as the largest users of the
single-use bioreactors during 2017-2026. In the terms of molecule type, the segment includes genemodified cells, stem cells, vaccines, monoclonal antibodies (MABS) and others. Among
aforementioned molecule types, monoclonal antibodies (MABS) is likely to witness strong growth
in the global single-use bioreactors market between 2017 and 2026.
Europe to Emerge as the Most Lucrative Market in the Global Single-Use Bioreactors Market
Europe is anticipated to be the most dominating region in the global single-use bioreactors market
during 2017-2026. Owing to the presence of some of the world’s leading pharmaceutical companies
in Europe, the region is likely to witness growth. The region is expected to account for the largest
share, due to the patient cliff of many biologics drugs in the region and the strong support by the
government to the biopharmaceutical companies in order to establish new therapies in biologics.
Also, the increasing use of single-use bioreactors in cell culture-based manufacturing is driving the
demand in the region. Single-use bioreactors are also becoming technologically advanced and are
also being provided at competitive cost.
Meanwhile, North America and APEJ are also likely to witness growth in the single-use bioreactors
market. Increasing investment by biopharmaceutical companies to establish their manufacturing
facilities is driving the growth in APEJ. Increasing focus on research activities and well-established
healthcare industry is resulting in the growth of the market in North America.
Request Sample Report @

Manufacturing advantages of multi-drug facilities continue to influence pharmaceutical companies towards meeting the growing demands by using the same facility to produce different drugs. In such facilities, single-use bioreactors are essential commodities that provide flexibility in the production of multiple drugs. By consuming minimum costs and saving time, single-use bioreactors can maintain the quality of drug production and eliminate the downtime caused by line clearance and cleaning validation.